💊 VRDN $1.6M Put Sale — A Desk Gets Paid to Own the Just-Approved Biotech Lower

📅 July 2, 2026 | 🤝 Negotiated Block Cross

✅ Updated 2026-07-06: next-day OPRA OI confirms a fresh opening short put (STO) — OI rose 6 → 5,006 (+5,000 = trade size, clean open). The get-paid-to-own read stands. See RESOLVED box below.

---

🎯 The Quick Take

Six days after Viridian Therapeutics received its FDA approval for Lumvoa (veligrotug), a desk sold 5,000 October $20 puts for ≈$1.6M — collecting premium in exchange for an agreement to own VRDN at an effective ≈$16.75. This is a negotiated block cross — not a sweep, not an aggressive directional bet — framing a bullish / income / willing-to-own view on a de-risked biotech sitting near its 52-week lows. The real question is whether Lumvoa's launch can ramp fast enough to keep the stock above ≈$16.75 through October 16.

---

📊 Company Overview

Viridian Therapeutics (NASDAQ: VRDN) is a now-commercial-stage biotechnology company focused on serious and rare diseases, with its core franchise in thyroid eye disease (TED):

• Industry: Healthcare — Biotechnology (rare / autoimmune disease)
• Market Cap: ≈$1.55 billion
• Current Price: ≈$19 (52-week range: $13.18–$34.29)
• Balance Sheet: $762M cash as of March 31, 2026 — management states this funds the company through profitability
• Lead Product: Lumvoa (veligrotug-vvze) — FDA-approved and launched June 26, 2026. A full IGF-1R antagonist vs. Tepezza's partial antagonism; the only TED drug approved for both active and chronic disease at launch. Priced at ≈$450,000 per treatment course.
• Pipeline: Subcutaneous autoinjector elegrobart (VRDN-003) with positive Phase 3 pivotal data in both active and chronic TED (REVEAL-1 and REVEAL-2); BLA targeted for Q1 2027.

Despite a 4-for-4 Phase 3 record and an early FDA approval ahead of the June 30 PDUFA date, VRDN trades near the lower half of its 52-week range — a textbook transition from "will it get approved?" to "how fast does it sell?" The binary regulatory risk is gone; the commercial execution risk is now front and center.

---

💰 The Trade — Plain English

A desk crossed 5,000 October $20 put contracts, selling them at $3.25 per share and collecting ≈$1.625M in upfront premium. With VRDN trading ≈$19.01 at the time, the $20 put is slightly in-the-money — this is not a far-out-of-the-money side bet. The writer is saying: "Pay me $1.6M today, and I'll agree to buy VRDN at $20 any time through October 16 — even though it's trading a dollar below that right now."

This is a 🤝 negotiated block cross — a pre-arranged transaction between two known counterparties, executed off the displayed book. There was no urgency, no sweep, no aggressive taker consuming market depth.

Full Trade Details:

Economics at a glance:

• Breakeven (effective entry): $20 strike − $3.25 premium collected = ≈$16.75
• Max Gain: ≈$1.625M (if VRDN closes above $20 at October 16 expiry; put expires worthless)
• Max Loss: Theoretically up to ≈$8.375M (if VRDN fell to $0; loss begins below ≈$16.75)

---

✅ RESOLVED — Next-Day OI Confirms a Fresh Opening Short (STO)

The July 6 pre-market OPRA snapshot (reflecting July 2 end-of-day) is in. Open interest ROSE from 6 to 5,006 — an exact, clean opening.

OI rose +5,000 — precisely the trade size — with zero transfer component. This is a textbook Sold to Open (STO): the desk opened a fresh 5,000-lot short put, getting paid ≈$1.6M to own VRDN at an effective ≈$16.75. The income / willing-to-own read stands exactly as written.

---

🤓 What This Actually Means — Plain English

Think of selling a put like collecting rent. The desk received $3.25 per share — ≈$1.625M total — in exchange for a contractual promise: "If VRDN falls below $20 by October 16, I'll buy 500,000 shares at $20 per share."

Since the premium collected was $3.25, the effective purchase price if assigned would be $20 − $3.25 = ≈$16.75 per share — the level the writer is apparently comfortable owning VRDN at.

Here is how this resolves at October 16 expiry:

• VRDN above $20 (best outcome for the writer): The put expires worthless; the desk keeps all ≈$1.625M in premium with no stock changing hands. Pure income.
• VRDN between $16.75 and $20 (assigned but net profitable): The put is exercised; the writer purchases 500,000 shares at the $20 strike. Net cost basis ≈$16.75 — still below today's ≈$19 spot. They own VRDN at a real-world discount, but have a gross "underwater" purchase price of $20.
• VRDN below $16.75 (loss zone): The writer starts losing money. At $13 (near the 52-week low), the loss on the position would be ≈$1.875M net of premium collected. At $10, the loss approaches ≈$3.375M.

Why is this framed as bullish / income?

The writer chose October 16 expiry — a window that captures Lumvoa's early launch trajectory, the first Q2 revenue print (early August), and the Roche Enspryng PDUFA (October 15). The ≈$16.75 effective entry sits comfortably above VRDN's 52-week nadir of $13.18. This reads as a desk that either (a) believes VRDN has a meaningful floor and wants to collect premium on that conviction, or (b) is genuinely comfortable owning the stock at ≈$16.75 if the launch disappoints. Either way — they think the floor holds.

What the tape proves vs. what it does not:

• ✅ PROVEN: The cross mechanism, the ≈$1.6M premium collected, the 5,000-contract size vs. prior OI of 6 (confirming a fresh opening short), and the unhedged structure (no simultaneous large stock block consistent with a delta hedge)
• 🔍 INFERRED: Bullish / income intent; willingness to own VRDN at ≈$16.75
• ❓ UNKNOWABLE from OPRA: Whether this is a covered put (writer holds long stock) or a naked short put; the identity of the desk; whether this is a standalone position or part of a larger portfolio hedge

---

📈 Technical Setup

YTD Performance

VRDN has had a dramatic year — peaking near $34 and now trading ≈$19, roughly half its highs. The June 26 FDA approval of Lumvoa triggered only a modest +12% bounce on June 29, a classic "buy-the-rumor, sell-the-news" pattern into an expected approval. The stock remains well below its 52-week high of $34.29, anchored by the open question of commercial execution. The desk writing this put at an effective ≈$16.75 entry is implicitly saying the stock's downside floor — even in a disappointing launch scenario — sits somewhere in the mid-teens, with $762M cash underpinning the balance sheet.

---

Gamma-Based Support & Resistance

VRDN's overall gamma profile is thin — characteristic of a small-cap specialty biotech with limited near-term options market depth. Most of the open interest is concentrated at a small number of round-dollar strikes. Here is what the gamma exposure map shows:

🔵 Support Levels (below current price):

• $18 — Secondary Support: Mixed gamma at this level (≈0.26 call / ≈0.13 put net GEX). Market makers have some stabilizing buying interest nearby; this acts as a light cushion.
• $17 — Stronger Support Floor: The highest sub-spot gamma concentration in the chain (≈0.50 net GEX, call-dominated). This is the most meaningful gamma magnet below current price — a natural dealer-buying zone. Notably, the 52-week low of $13.18 sits well below this level, giving the $17 floor some breathing room before disaster territory.

🟠 Resistance Levels (above current price):

• $20 — Primary Resistance Wall (the put's strike!): The strongest call gamma concentration across the entire VRDN chain (≈0.64 net GEX). This is a natural ceiling just above current spot — dealers are long gamma here and will shade short into any rally. It is not a coincidence that this 5,000-contract put was written exactly at the dominant gamma wall: if VRDN cannot break $20, the writer keeps the full ≈$1.6M; if it does break above $20, the puts expire out-of-the-money at expiry anyway.
• $21–$22 — Secondary Resistance Band: Lighter gamma (≈0.10–0.11 net GEX each). The path above $20 becomes easier once dealers at that level are neutralized.
• $25 — Extended Upside Target: Small gamma accumulation (≈0.15 net GEX); a realistic medium-term bull case level if launch traction materializes.

Big picture: The gamma structure creates a ceiling at $20 (the exact put strike) and a floor around $17–$18. The put writer's ≈$16.75 breakeven sits just below the gamma support zone — a reasonably informed level absorbing meaningful downside before real losses kick in.

---

Implied Move — Options Market Pricing

For the July 17 monthly OPEX (15 days out), the options market is pricing a ±11.5% (≈$2.20) move — suggesting a near-term range of roughly $16.86 to $21.26.

Key observations:

• The lower bound of the July implied move range (≈$16.86) is almost exactly the put writer's ≈$16.75 breakeven. If the market's 1-standard-deviation range for the NEXT 15 days already reaches the put's breakeven, the 3.5-month October window sees substantially more potential downside.
• The upper bound (≈$21.26) is above the $20 gamma wall — suggesting the market sees a realistic path above $20 within the near term.
• The October $20 put sits well beyond this near-term implied move window; that expiry will capture the early August Q2 earnings binary and the October 15 Roche Enspryng PDUFA — both material volatility events.

Translation for regular traders: VRDN is a volatile, post-catalyst biotech where the market is pricing ±11.5% for a single month. At $3.25 for a 3.5-month put (≈17% of strike), the put writer is collecting elevated premium — but they are accepting that premium in exchange for real assignment risk on a stock that can move dramatically on a single clinical or regulatory headline.

---

🎪 Catalysts

✅ Past Catalysts (Already Happened — Binary Risk Removed)

• June 26, 2026 — FDA Approval and Immediate Commercial Launch of Lumvoa: Approved four days ahead of the June 30 PDUFA date; physicians could prescribe within a day of the announcement. Lumvoa carries Breakthrough Therapy and Priority Review designations and covers both active and chronic TED — a broader label than Tepezza's original approval. Launch price ≈$450,000 per treatment course.

• March 30, 2026 — REVEAL-1 Phase 3 Positive (elegrobart, active TED): Subcutaneous autoinjector hit primary endpoint; 54% / 63% proptosis responders (Q4W/Q8W arms) vs. 18% placebo. Clean tolerability.

• May 5, 2026 — REVEAL-2 Phase 3 Positive (elegrobart, chronic TED): Second pivotal win; elegrobart is now the only subcutaneous TED program with positive Phase 3 data in both active and chronic disease.

• Post-approval analyst upgrades: Wedbush raised its price target to $43; Goldman Sachs to $39, Truist to $38, RBC Capital to $35, William Blair reiterated Outperform. Consensus is "Strong Buy / Buy" with average price targets in the $32–$43 range — substantially above current ≈$19 trading.

---

📅 Upcoming Catalysts (Directly Affecting This Trade Before Oct 16 Expiry)

• Early August 2026 — Q2 2026 Earnings: The first quarter capturing Lumvoa launch revenue. This is the critical near-term datapoint: gross-to-net realization (actual revenue vs. ≈$450k list price), payer coverage breadth, physician onboarding, and infusion-site adoption metrics. RBC has noted that more meaningful Lumvoa revenue is a 2027 story, so Q2 sets early expectations. A soft print or cautious guidance could pressure VRDN toward the ≈$16.75 breakeven zone.

• October 15, 2026 — Roche Enspryng (satralizumab) PDUFA (competitive): FDA priority review for the first subcutaneous, at-home IL-6R-mechanism TED option. SatraGO-2 showed 53% vs 23% proptosis response; SatraGO-1 had mixed results. A positive FDA decision would arrive the day before this $20 put expires on October 16 — making the final week of this trade's life potentially binary. Enspryng approval would intensify competition and could temporarily pressure VRDN's stock.

🔭 Beyond October 16 (Longer-Term Context)

• Q1 2027 — Elegrobart (VRDN-003) BLA Submission: The subcutaneous autoinjector program that would be VRDN's next major de-risking catalyst and a key long-term differentiator vs. IV-only competitors.
• EMA Decision on Veligrotug: MAA accepted for review February 2026; CHMP opinion pending.
• Lumvoa long-term durability data: Ongoing readouts supporting the commercial physician-access story.

---

💡 What This Means for Different Traders

🎰 YOLO Trader

The put write itself requires significant capital and margin — you are not the desk doing this 5,000-lot block. But if you share the underlying bullish thesis and want leveraged upside exposure on VRDN's launch story, buying October $20 or $22.50 calls gives you defined-risk exposure to a rally without the open-ended downside of short puts. The early August Q2 earnings would be the catalyst. Biotech options carry high implied volatility, so near-term calls can be expensive relative to the expected move — size small and stay within what you can lose entirely.

Risk level: Very High | Nature: Defined-risk long call | Catalyst: August earnings

📈 Swing Trader

The core thesis: VRDN executed a clean regulatory cycle (4-for-4 Phase 3, early FDA approval); the stock went from $34 to $19 not on fundamental failure but on "prove-the-launch" sentiment repricing. If Q2 earnings (early August) show even modest early Lumvoa traction — prescriber access, payer coverage, reasonable gross-to-net — the stock has a legitimate path back toward $22–$25, where the secondary gamma resistance sits.

Best entry setup: Watch for any dip toward $17–$18 (the gamma support zone identified above) for a more favorable risk/reward than the current ≈$19. Use the gamma structure as a reference: hold above $17, reassess if it breaks.

Watch for: Payer coverage announcements, Lumvoa prescriber counts, any Amgen Tepezza market-share commentary, and Enspryng Phase 3 safety details ahead of the October 15 PDUFA.

Risk level: Medium | Timeframe: 2–4 months

💰 Premium Collector

This trade is the archetype for what you do: get paid to agree to own a de-risked name at a discount. The put writer collected ≈17% of the $20 strike in premium for 3.5 months — elevated by biotech implied volatility. If you want to replicate this at retail scale with a more conservative tilt, consider the October $17.50 or $15 puts, which would collect less premium but put the effective entry deeper in the lower range of the 52-week band.

Critical discipline: Only write as many put contracts as you are genuinely willing to absorb as stock at assignment. Biotech names can drop 30–50% on a single clinical safety signal, competitive approval, or disappointing commercial data. Never write more than you can fund at $20 per share in stock.

Risk level: Medium–High (open-ended to the downside) | Income potential: Elevated; $VRDN IV supports attractive credit for defined-date risk

🌱 Beginner — What's Actually Happening Here

Here is the plain-English version of the whole trade:

Someone made a deal. They said: "Pay me $3.25 per share today — ≈$1.6M total — and in exchange I'll agree to buy VRDN stock at $20 per share if it's trading below that price on October 16." They collect the money upfront. If VRDN stays above $20 by October 16, they walk away with ≈$1.6M and never touch a share of stock. If it falls below $20, they end up buying the shares — but their real cost is $20 − $3.25 = $16.75 per share.

This is called selling a put or a put-write. It is a popular income strategy when you are willing to own a stock at a lower price than it currently trades.

The risk: if VRDN dropped to $5 — which can absolutely happen in biotech — the writer would still be obligated to buy at $20, losing roughly $14.25 per share on 500,000 shares (≈$7.1M loss). This is why short puts need to be sized very carefully and why this strategy is generally not appropriate for beginners until you understand margin, assignment, and position sizing.

---

⚠️ Risk Factors — Honest Limits

A short put on a volatile small-cap biotech carries real open-ended downside. Here is what could go wrong:

• 🚨 Open-ended downside. The maximum loss is not capped — a short put loses money all the way to zero. Small-cap biotechs can drop 40–60% in a day on a clinical safety signal, a missed endpoint, or a surprise competitive approval. VRDN at $5 or below would represent a multi-million dollar loss for the writer of these puts.

• 💊 Launch execution risk. VRDN's Lumvoa is priced at ≈$450k/course, and revenue depends on specialty-pharmacy buy-and-bill economics, payer coverage (notoriously slow in specialty disease), and physician practice setup. RBC flagged that more meaningful Lumvoa revenue is a 2027 story. A soft Q2 print — or cautious management commentary on access — could push the stock toward or below ≈$16.75.

• 🏥 Roche Enspryng PDUFA (October 15) — the day before expiry. An FDA approval of the first subcutaneous, at-home TED option could rattle the market and compress VRDN's early commercial story at the worst possible moment — the final trading day before this put expires.

• 🧬 Amgen subcutaneous Tepezza. Amgen is developing an on-body injector version of Tepezza that would directly challenge elegrobart's long-term convenience advantage. Strong clinical data from Amgen's SC program would intensify competitive pressure on the VRDN franchise.

• 📉 Sentiment overhang. Despite a flawless 4-for-4 clinical and regulatory record, VRDN trades near 52-week lows — a "prove-the-launch" setup where even mild disappointment is punished. The stock has limited technical support between ≈$17 (gamma floor) and the 52-week low of $13.18.

• 📊 Analyst consensus vs. price reality gap. Average analyst price targets sit in the $32–$43 range — far above ≈$19. That gap reflects either a buying opportunity or a market that disagrees with sell-side optimism on launch timing. The put writer is on the "buying opportunity" side of that debate.

• ❓ Covered vs. naked unknown. The OPRA tape cannot tell us whether this short put is covered by an existing long stock position (insulating the writer from net losses below ≈$16.75 to the extent stock gains offset) or is a naked short put with full open-ended risk. We report what the tape shows — account structure and counterparty identity remain unknowable.

---

🎯 The Bottom Line

Here's the deal: Six days after Lumvoa's FDA approval, a desk sold 5,000 October $20 puts for ≈$1.625M — getting paid to agree to own a just-approved, de-risked biotech near its 52-week lows. The effective ≈$16.75 entry sits comfortably above the 52-week nadir of $13.18 and just below the $17 gamma support zone. The $762M cash balance provides meaningful balance-sheet runway.

This is a bullish / income / willing-to-own trade — not a declaration that VRDN is heading to $30. The writer is not urgently buying the stock; they're comfortable owning it at a discount to today's price if the launch stumbles, and they're collecting ≈$1.6M in premium for making that commitment.

What this trade implicitly bets on:

• ✅ VRDN does not collapse below ≈$16.75 over 3.5 months
• ✅ The Lumvoa launch shows at least early directional traction at August Q2 earnings
• ✅ Roche Enspryng's October 15 PDUFA does not crater VRDN the day before expiry
• ✅ $762M in cash prevents any near-term existential balance-sheet risk

What to watch: The early August Q2 earnings print is the next real signal. Look for: gross-to-net realization (what VRDN actually receives vs. ≈$450k list), prescriber counts, payer coverage wins, and infusion-site onboarding commentary. That data will either support or undermine the put writer's ≈$16.75 floor thesis.

Mark your calendar:

• 📅 July 3, 2026 (pre-market, ≈06:30 ET): Next-day OPRA OI snapshot — confirms size > OI opening
• 📅 Early August 2026: Q2 2026 earnings — first Lumvoa revenue print (exact date TBD by company)
• 📅 October 15, 2026: Roche Enspryng PDUFA
• 📅 October 16, 2026: $20 put expiry

Real talk: this writer has conviction in the floor, not necessarily in explosive upside. They are content to either pocket ≈$1.6M if VRDN stays afloat through October — or to own a commercial-stage biotech with $762M cash, a validated product, and a ≈$1.9B addressable market at a ≈$16.75 cost basis. Whether that conviction is correct depends on a commercial story that is still being written, with the next chapter arriving in early August.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. Short puts carry open-ended downside risk and require significant margin collateral. This analysis is for educational purposes only and does not constitute financial advice. Past option flow activity does not guarantee future results. Biotechnology stocks can experience sudden, severe price declines on clinical, regulatory, or competitive events. The trade discussed reflects the activity of a third-party market participant whose full portfolio context, hedging intentions, and risk parameters are unknown. Always conduct your own due diligence and consider consulting a licensed financial advisor before trading. Options trading may result in the loss of the entire amount invested or more.

---

About Viridian Therapeutics: Viridian Therapeutics is a commercial-stage biotechnology company focused on serious and rare diseases. Its FDA-approved product Lumvoa (veligrotug-vvze), launched June 26, 2026, is the first direct competitor to Amgen's Tepezza in the treatment of thyroid eye disease, with approval covering both active and chronic disease. Market cap ≈$1.55 billion; $762M cash as of March 31, 2026.

Last updated: 2026-07-06 — open/close RESOLVED via next-day OPRA OI: Oct-16 $20P OI 6 → 5,006 (+5,000 = trade size) = fresh opening short (STO), get-paid-to-own read confirmed.